Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline

被引:0
作者
Francesco Panza
Vincenzo Solfrizzi
Anna M. Colacicco
Alessia D’Introno
Cristiano Capurso
Rossella Palasciano
Orlando Todarello
Sabrina Capurso
Vincenza Pellicani
Antonio Capurso
机构
[1] University of Bari - Policlinico,Department of Geriatrics, Center for Aging Brain, Memory Unit
[2] University of Foggia,Department of Geriatrics
[3] University of Bari,Department of Neurological and Psychiatric Sciences
来源
Aging Clinical and Experimental Research | 2006年 / 18卷
关键词
Alzheimer’s disease; cerebrovascular disease; mild cognitive impairment; predementia syndrome; total cholesterol; vascular dementia;
D O I
暂无
中图分类号
学科分类号
摘要
Data concerning the treatment of lipoprotein disturbances in patients with cerebrovascular disease (CVD) are less robust than those for coronary heart disease (CHD), raising clinical questions as to which is the appropriate therapeutic approach to stroke patients. Although observational cohort studies have failed to demonstrate an association between lipoprotein disorders and stroke incidence, recently completed trials of subjects at risk for CHD have shown that statins reduce not only the risk of myocardial infarction and death, but also that of brain infarction and transient ischemic attacks. At present, it seems reasonable to conclude that stroke patients with undesirable lipid profiles who have a history of CHD should receive specific treatment for the lipid disorder. Recommendations are more problematic for stroke patients with lipid disorder but no history of CHD. Furthermore, many of the risk factors for CVD and vascular dementia (VaD), including serum total cholesterol (TC), lipoprotein(a), diabetes, atrial fibrillation, hypertension, apolipoprotein E levels, and atherosclerosis, have also been shown to increase the risk of Alzheimer’s disease (AD). In a recent study, we estimated the prevalence, incidence and rate of progression of Mild Cognitive Impairment (MCI) to dementia, and correlated vascular risk factors with incident MCI and its progression to dementia. We evaluated 2963 individuals from the population-based sample of 5632 subjects 65–84 years old of the Italian Longitudinal Study on Aging, with a 3.5-year follow-up. We found a progression rate to dementia (all causes) of 3.8/100 person-years. Furthermore, age was a risk factor for incident MCI, while education was protective, and serum TC evidenced a non-significant borderline trend for a protective effect. There was a non-significant trend for stroke as a risk factor of progression of MCI to dementia. In conclusion, in our population, among MCI patients who progressed to dementia, 60% progressed to AD and 33% to VaD. Vascular risk factors and CVD may influence the development of MCI and the rate of progression to dementia.
引用
收藏
页码:144 / 148
页数:4
相关论文
共 79 条
  • [1] Amarenco P(2004)Stroke prevention, blood cholesterol, and statins Lancet Neurol 3 271-8
  • [2] Lavallee P(2004)Vascular risk and genetics of sporadic late-onset Alzheimer’s disease J Neural Transm 111 69-89
  • [3] Touboul PJ(1995)Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts Lancet 346 1647-53
  • [4] Panza F(1995)An overview of trials of cholesterol lowering and risk of stroke Arch Intern Med 155 50-5
  • [5] D’Introno A(2002)MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial Lancet 360 7-22
  • [6] Colacicco AM(2002)Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial Lancet 360 1623-30
  • [7] Hebert PR(2003)Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial —Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial Lancet 361 1149-58
  • [8] Gaziano JM(2003)Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study Cerebrovasc Dis 16 389-95
  • [9] Hennekens CH(1995)Interactions of apolipoprotein E genotype; total cholesterol level; age; and sex in prediction of Alzheimer’s disease: a case-control study Neurology 45 1092-6
  • [10] Shepherd J(1998)Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease Neuroepidemiology 17 14-20